XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for cancer (lat. Carcinoma) early detection, monitoring, and evaluation of response to therapy. By exploiting the natural immune response to early-stage cancer and the proprietary platform technology Combinatorial Proteomic®, XEPTAGEN has discovered predictive, prognostic and early response tumour markers that lead to earlier and much more accurate detection of developing carcinomas. The company's mission is to include creating innovative tools that improve the clinical management of patients with liver, colorectal and prostate cancers (lat. Prostate Carcinoma).